This study aimed to evaluate and compare the efficacy of ketamine and lidocaine infusion in patients with chronic peripheral neuropathic pain.

Patients who received intravenous ketamine infusion and the other patient group who received intravenous lidocaine infusion were evaluated in the study. Pain scores and quality of life were assessed with scales before treatment at two weeks, two months, and six months after treatment.

This study, it was aimed to evaluate and compare the efficacy of intravenous infusion of ketamine and lidocaine, which have been known and used in pain management and which have recently increased interest in the treatment of peripheric neuropathic pain.

Inclusion Criteria:

• 18-65 years of age
• Patients with peripheral neuropathic pain (radicular neuropathy, diabetic neuropathy, complex regional pain syndrome type 2, traumatic peripheral nerve injury, trigeminal neuralgia, postherpetic neuralgia)
• Patients who was evaluated by DN4 scores with of ≥4 points

Exclusion Criteria:

• Patients with central nervous system disease .
• Patients with cancer related neuropatic pain.
• Patients with central neuropathic pain patterns.
• Patients with renal, hepatic, cardiovascular, and psychiatric diseases.
• Patients whose treatment could not be completed due to side effects or other reasons.
• Patients who had lost their follow-up .

For the retrospectively designed study, data (electronic database program of the hospital and files) of the patients admitted to the algology clinic with neuropathic pain symptoms between January 2021 and May 2021 were evaluated.